1	Emergence of the Novel Sixth Candida auris Clade VI in Bangladesh
2	Tahsin Khan ¹ , Naimul Islam Faysal ¹ , Md Mobarok Hossain ¹ , Syeda Mah-E-Muneer ² , Arefeen
3	Haider ¹ , Shovan Basak Moon ¹ , Debashis Sen ³ , Dilruba Ahmed ³ , Lindsay A. Parnell ⁴ ,
4	Mohammad Jubair ¹ , Nancy A. Chow ⁴ , Fahmida Chowdhury ² , Mustafizur Rahman ^{1,2}
5	
6	¹ Genome Centre, Infectious Diseases Division, icddr,b, Mohakhali, Dhaka-1212, Bangladesh
7	² Emerging Infections, Infectious Diseases Division, icddr,b, Mohakhali, Dhaka-1212,
8	Bangladesh
9	³ Mycology Laboratory, icddr,b, Mohakhali, Dhaka-1212, Bangladesh
10	⁴ Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia,
11	USA
12	
13	Correspondence to:
14	Mustafizur Rahman, PhD, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh;
15	mustafizur@icddrb.org; Telephone number: +880 2 9840523-32
16	
17	ABSTRACT
18	Candida auris, initially identified in 2009, has rapidly become a critical concern due to its
19	antifungal resistance and significant mortality rates in healthcare-associated outbreaks. To date,
20	whole-genome sequencing (WGS) has identified five unique clades of C. auris, with some
21	strains displaying resistance to all primary antifungal drug classes. In this study, we presented
22	the first WGS analysis of C. auris from Bangladesh, describing its origins, transmission
23	dynamics, and antifungal susceptibility testing (AFST) profile. Ten C. auris isolates collected
24	from hospital settings in Bangladesh were initially identified by CHROMagar [™] Candida Plus,
25	followed by VITEK [®] 2 system and later sequenced using Illumina NextSeq 550 system. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to quide clinical practice.

26 Reference-based phylogenetic analysis and variant calling pipelines were used to classify the 27 isolates in different clades. All isolates aligned ~90% with the Clade I C. auris B11205 reference genome. Of the ten isolates, eight clustered with Clade I isolates, highlighting a South 28 29 Asian lineage prevalent in Bangladesh. Remarkably, the remaining two isolates formed a 30 distinct cluster, exhibiting >42,447 SNP differences compared to their closest Clade IV counterparts. This significant variation corroborates the emergence of a sixth clade (Clade VI) 31 32 of C. auris in Bangladesh, with potential for international transmission. AFST results showed that 80% of the C. auris isolates were resistant to fluconazole and voriconazole, whereas Clade 33 34 VI isolates were susceptible to azoles, echinocandins, and pyrimidine analogue. Genomic 35 sequencing revealed *ERG11* Y132F mutation conferring azole resistance while *FCY1* S70R mutation found inconsequential in describing 5-flucytosine resistance. Our study underscores 36 37 the pressing need for comprehensive genomic surveillance in Bangladesh to better understand 38 the emergence, transmission dynamics, and resistance profiles of *C. auris* infections. Unveiling the discovery of a sixth clade (Clade VI) accentuates the indispensable role of advanced 39 40 sequencing methodologies.

41

42 **IMPORTANCE**

Candida auris is a nosocomial fungal pathogen which is commonly misidentified as other 43 44 *Candida* species. Since its emergence in 2009, this multi-drug resistant fungus has become one 45 of the five urgent antimicrobial threat by 2019. Whole Genome Sequencing (WGS) has proven to be the most accurate identification technique of C. auris which also played a crucial role in 46 the initial discovery of this pathogen. WGS analysis of C. auris has revealed five distinct clades 47 48 where isolates of each clade differ among themselves based on pathogenicity, colonization, infection mechanism as well as other phenotypic characteristics. In Bangladesh, C. auris was 49 50 1st reported in 2019 from clinical samples of a large hospital of Dhaka city. To understand the

origin, transmission dynamics and antifungal resistance profile of *C. auris* isolates circulating
in Bangladesh, we conducted WGS based surveillance study on two of the largest hospital
settings in Dhaka, Bangladesh.

54

55 INTRODUCTION

Candida auris, an emerging multidrug-resistant pathogen, imposes a serious threat to global 56 57 public health owing to its high virulence and transmissibility in hospital settings [1]. Since the first report in 2009 in Japan, this nosocomial pathogen has already been reported in over 50 58 59 countries, colonizes human skin and hospital environments, and causes invasive candidiasis, especially in critically ill and immunosuppressed patients [2-4]. Patients with C. auris infection 60 or colonization frequently exhibit other underlying health conditions and comorbidities, such 61 62 as diabetes, cardiovascular diseases, liver diseases, chronic or acute kidney failure, solid tumor or malignancies [5]. 63

Whole-genome sequencing (WGS) and matrix-assisted laser desorption ionization-time of 64 65 flight (MALDI-TOF MS) platforms are the best-suited options to correctly identify C. auris [6]. Worldwide, WGS analysis has grouped C. auris into five distinct genotypic clades based 66 on 40,000 to >200,000 single nucleotide polymorphism (SNPs) such as Clade I (South Asia), 67 Clade II (East Asia), Clade III (Africa), Clade IV (South America), and Clade V (Iran) [3, 7, 68 69 8]. Though the reasons for the reported independent and simultaneous emergence in different 70 geographical regions are unknown, animal reservoirs and environmental changes are 71 speculated to accelerate this situation [9]. Each clade harbors highly related isolates due to local transmission and clonal expansion within countries [10, 11]. However, analysis from molecular 72 73 epidemiological investigations, outbreaks, and individual cases also revealed genetic 74 complexity suggesting multiple introductions followed by local transmissions in different 75 countries [12].

76 Antifungal resistance seems to be clade specific [13]. Clade II isolates are generally more 77 susceptible to antifungal agents, whereas Clade I, III and IV are highly resistant [1, 8, 14]. Only 2/5 identified isolates of Clade V were found resistant to fluconazole but were susceptible to 78 79 triazoles, echinocandins, and amphotericin B [15, 16]. Nonetheless, antifungal resistances were observed on all five clades to currently used antifungal drugs such as azoles (fluconazole, 80 voriconazole, itraconazole, and isavuconazole), polyenes (amphotericin B), echinocandins 81 82 (caspofungin, micafungin, and anidulafungin), and pyrimidine analogue flucytosine [11, 17-19]. Genomic level inspections revealed clade-specific azole-resistant mutations in ERG11: 83 84 Y132F or K143R in Clade I, F126T/L in Clade III, Y132F in Clade IV, and Clade V [3, 7]. Numerous mechanisms responsible for antifungal resistance have been reported for C. auris, 85 such as echinocandin-resistant FKS1:S639/F/P/Y, and FKS1:S635Y/P mutations, 5-flucytosine 86 resistant FCY1:S70R, FCY2:M128fs (frameshift), ADE17:G45V and FUR1:1A33 [20, 21]. 87 Resistance mechanisms for amphotericin B are not well documented; however, WGS analysis 88 has identified several nonsynonymous polymorphisms that might infer resistance [22]. 89 Bangladesh (BD) is located in South Asia where fungal outbreaks have been widely reported 90 91 [23-25]. The first reported case of C. auris in Bangladesh was in 2019, whereas India and 92 Pakistan reported in 2013 and 2015 respectively [7, 26, 27]. Dutta et al., 2019 reported C. auris 93 infections in 19 patients that showed resistance to voriconazole (18/21), fluconazole (14/21), 94 and amphotericin B (5/21) [28]. A recent study that conducted AFST for major fungal pathogens in different hospital settings in Bangladesh also reported C. auris resistance against 95 96 fluconazole (100%), itraconazole (100%), voriconazole (33.3%), and amphotericin B (100%) [29]. Monitoring the circulating clades and observing the resistance pattern of C. auris is 97

99 data for *C. auris* in Bangladesh, we conducted WGS analysis on 10 *C. auris* isolates collected

crucial to prevent spread and transmission. Considering the absence of genomic surveillance

98

100 from intensive Care unit (ICU) and neonatal intensive care unit (NICU) patients from two

101 national hospitals in Bangladesh. We report the emergence of a sixth clade (Clade VI),102 circulating along with Clade I isolates in Bangladesh.

103

104 **RESULTS**

105 Patient Information.

Ten *C. auris* isolates representing eight ICU patients and two NICU patients were described in this study. Patients were admitted with various underlying health complications; none had candidemia (**File S1**). Among the patients, only one patient (101022) from ICU had previous travel history to the United Arab Emirates within one year of enrolment. Overall, 40% (4 patients from ICU) developed nosocomial colonization with *C. auris*, and none received any antifungal treatment since patients either expired or were discharged by the time the test result was released (Table 1).

TABLE 1: Patient metadata of sequenced *Candida auris* isolates.

114

115 WGS SNP Calling and Phylogeny Analysis: Emergence of a Novel Clade.

116 Whole genome-based SNP calling was performed to distinguish all BD isolates in different clades, incorporating a total of 25 C. auris isolates that represent the known five clades (File 117 S2). Around 92.68% (SD ± 1.17) reads of BD isolates mapped with the reference B11205 with 118 119 an average GC content of 44.41% (SD ± 0.15) (File S3). Phylogenetic analysis revealed that 120 BD-ICU isolates (Sample ID 101019, 101008, 101009, 101022, 101077, 101082, 101101, and 101087) clustered closely with Clade I with a maximum SNP difference of 163 SNPs (Fig. 1, 121 File S4). Notably, these isolates differed by only ≤ 17 SNPs from each other except isolates 122 123 101019 and 101022. The isolate (101022) collected from the ICU patient who traveled to UAE was separated by only 18 SNPs from the UAE B14000 isolate. Isolate 101019 had the highest 124 125 SNP differences with other Clade I BD-ICU isolates (87-102 SNPs). Within the Clade I 126 clusters, Clade I BD isolates had closer resemblance to UK 15B5 isolate (51-86 SNPs) than those from India (108-155 SNPs), Pakistan (109-148 SNPs) and New Jersey, USA (124-163). 127 Interestingly, the BD-NICU isolates (102096, and 102170) clustered separately from all known 128 clade isolates (Fig. 1). These two isolates differed by only 68 SNPs and were genetically 129 distinct from all the clades by at least 42,447 single-nucleotide polymorphisms, and hence, 130 formed a novel clade, Clade VI [7]. South American Clade (Clade IV) was the closest neighbor 131 132 (>42,447 SNPs) for Clade VI, whereas the Iranian Clade (Clade V) was the most distant neighbor (>254,068 SNPs). To pinpoint the origin of this novel clade, we inquired the neonates' 133 134 parents about any international travel history, but none had any in 2020 or before. The two neonates were born in different hospitals, but later they were transferred to the NICU of study 135 hospital. It was unknown whether their parents were suffering from fungal colonization or 136 137 infections; or whether these neonates acquired C. auris colonization during birth or from the previous hospitals. To investigate the emergence of this novel clade, phenotypic differences 138 between the Clade I and Clade VI isolates were observed and are described in Table 2 (Fig S1). 139 140

TABLE 2: Phenotypic differences observed between BD Clade I and Clade VI isolates of *Candida auris* at different timelines (A) 24 hours (B) 48 hours and (C) 72 hours.

143

FIG 1. Phylogenetic tree based on SNPs of 35 *C. auris* isolates. (A) Representation of known
five clades with novel Clade VI of *C. auris*. (B) Distances between Clade IV and novel Clade
VI. All the BD isolates from our study are represented by dark blue color. Eight BD-ICU
isolates clusters with reference isolate and 5 Clade I isolates from different countries. Two BDNICU isolate (102096, and 102170) clusters together distinctly from other clades forming
novel Clade VI. Isolate B11243 of Clade IV has the closest SNP distances from Clade VI

isolates. (C) Clade-wise heatmap of SNP distances among all *C. auris* isolates used in thisstudy.

152

153 Molecular Resistance Mechanisms.

All the BD isolates were screened for mutations associated with antifungal resistance. For 154 fluconazole and other triazole resistance, ERG11, CDR1, TAC1B and MRR1A gene mutations 155 156 were screened in several positions leading to increased MIC values. All BD-ICU isolates of Clade I harbored ERG11 Y132F substitution. No mutations were detected in CDR1, TAC1B 157 158 and MRR1A genes. No known FKS1 gene mutation was observed in BD-ICU isolates which is reflected by susceptibility to caspofungin in AFST results (Table 3). FCY1 S70R mutation 159 160 which confers 5-flucytocine resistance was detected in all BD-ICU isolates by genomic 161 analysis. No known mutations in ERG3 and ERG6 genes were detected which could explain the amphotericin B resistance in isolate 101022. Surprisingly, Clade VI isolates from BD-162 NICU patients had no known mutations in any of the drug resistance genes (Table 3). 163

164

TABLE 3: Results of known mutation analysis and antifungal susceptibility test for azoles,polyenes, and echinocandins.

167

168 Antifungal Susceptibility Testing (AFST).

Antifungal susceptibility testing was performed on all BD *C. auris* isolates against fluconazole, voriconazole, caspofungin, and amphotericin B (Table 3). Based on U.S. CDC tentative breakpoints, all BD-ICU isolates were highly resistant to fluconazole (MIC 256 mg/L) and voriconazole (MIC 32 mg/L). Isolate 101022 collected from patient with recent travel history to the United Arab Emirates additionally showed resistance to amphotericin B (MIC 2 mg/L) along with fluconazole and voriconazole. No resistance was observed for caspofungin in BD-

175 ICU isolates. On the contrary, BD-NICU isolates representing Clade VI were susceptible to 3 major antifungal drug classes. However, BD-NICU isolate 102170 demonstrated resistance to 176 amphotericin B (MIC 2 mg/L). Only isolate 101019 of Clade I harboring FCY1 S70R mutation 177 showed resistance against 5-flucytosine in both disk diffusion and automated VITEK®2 178 methods, while other Clade I isolates showed sensitivity in both methods even though these 179 harbor the same mutation (Table 4). Mutational analysis on the resistance profile aligned with 180 181 the AFST results except for isolate 101022 and 102170; no known mutation was found that 182 confer amphotericin B resistance.

183

TABLE 4: Results of 5-flucytosine antifungal susceptibility test by disk diffusion and
VITEK[®]2 method.

186

187 DISCUSSION

Candida auris, first detected in Bangladesh in 2019, has emerged as a global multi-drug 188 189 resistant healthcare-associated pathogen [29]. WGS-based approach revealed the circulation of 190 Clade I lineages, and the emergence of a new Clade VI in Bangladesh. Six BD-ICU Clade I 191 isolates (101008, 101009, 101077, 101082, 101101, 101087) collected from adult patients, who never traveled overseas, are phylogenetically closest to each other (SNPs range 3-17), 192 193 indicating the ongoing local and clonal transmission [12, 30]. The isolate 101022 from an ICU 194 patient who previously traveled to UAE and died after admission was only 18 SNPs different 195 than UAE B14000, indicating possible Clade I transmission from UAE to Bangladesh.

196 The genome sequencing approach separated the clades of *C. auris* by tens of thousands of SNP 197 differences [7]. The ~42,447 SNPs difference of BD-NICU isolates (102096 and 102170) 198 indicate the emergence of the new clade, Clade VI, in Bangladesh. Though tracing was not 199 possible to identify the source of this nosocomial infection in neonates, it is evident that Clade

200 VI is circulating in Bangladesh. By the time of writing this manuscript, a preprint published by 201 a group of researchers from Singapore claimed the presence of a new clade separated by >36,000 SNPs from all known five clades of C. auris [31]. These isolates namely isolate A 202 203 (LIMS ID F3485, Biosample SAMN36753178), Isolate B (LIMS ID F1580, Biosample 204 SAMN36753179), Isolate C (LIMS ID F0083, Biosample SAMN36753180), and 102096 from 205 our study (SRR24877248) were distinct by at least 70 SNPs [31]. Isolate C of the novel clade 206 was collected from the blood of a Bangladeshi patient in 2018, who was airlifted directly to 207 Singapore General Hospital to have treatment, and was initially classified as Clade IV [30]. 208 The presence of candidemia in this patient indicates the undetected circulation of novel C. auris clade in Bangladesh and a later transfer to Singapore in 2018 before the first detection of C. 209 210 auris in Bangladesh in 2019 [28]. It is surprising to note that even though Clade I and Clade 211 VI isolates are circulating in Bangladesh simultaneously, Clade VI isolates acquired no known 212 mutations and showed no phenotypic resistance except amphotericin B (Isolate 102170). It is 213 of utmost importance to conduct nationwide genomic surveillance of prospectively collected 214 C. auris isolates along with archived isolates stored at different hospitals in Bangladesh to 215 understand the origin and transmission dynamics of Clade VI.

216 Clade I BD-ICU isolates showed the general trend of azole resistance for both mutational (genotypic) and AFST (phenotypic) results against fluconazole and voriconazole [7]. 217 218 Surprisingly, these isolates showed inconsistency for 5-flucytosine resistance pattern except 219 for isolate 101019. A similar observation was reported from a 29-year-old woman residing in 220 New Jersey, who was diagnosed with severe short bowel syndrome [20]. She underwent a 221 multi-visceral transplantation surgery and during her post-operative period of 72 days, the 222 patient developed refractory fungal peritonitis. Nineteen C. auris isolates were obtained from the patient at various time intervals. While the initial 12 isolates collected within the initial 33 223 224 days demonstrated sensitivity to 5-flucytosine, the subsequent 7 isolates obtained between days 225 33 and 72 exhibited resistance to this antifungal agent. Genomic analysis of these isolates 226 revealed the presence of the FCY1 S70R mutation in all 19 isolates. The authors argued FCY1 S70R mutation to be inconsequential in describing 5-flucytosine resistance. The 227 228 findings in our study reflected the discrepancy between FCY1 S70R mutation and resistance 229 pattern for Clade I isolates, strengthening the argument of inconsequential behavior of FCY1 S70R mutation in describing the 5-flucytosine resistance. Two BD-NICU isolates 230 231 representing Clade VI exhibited no resistance to the antifungals tested (except amphotericin B for Isolate 102170) and harbored no known mutations conferring resistance. Active clinical 232 233 surveillance, monitoring of clinical symptoms, and extensive epidemiological investigation 234 will accelerate understanding of the significance of this newly discovered sixth clade of C. 235 auris.

236

237 LIMITATIONS

Our study presents the WGS-based approach to detect the circulation of C. auris clades for the 238 239 first time in Bangladesh. The isolates sequenced in this study were collected from the archived 240 samples in 2021, as part of regular surveillance to monitor infections and colonization 241 associated with ICU/NICU admitted patients, tracing the contacts of C. auris positive cases was not performed at that time. The small sample size in this study may not be the 242 243 representative picture of C. auris circulation in Bangladesh. Including a large sample size 244 would increase the chances of capturing other undetected clades circulating in Bangladesh. Long-read sequencing would ensure the recovery of the nearly full genome and the 245 246 comprehensive genomic study on the antifungal resistance profile. Overall, our study 247 demonstrates the necessity of C. auris genomic surveillance to understand the transmission dynamics, pathobiology and containment of this urgent antimicrobial-resistant threat in 248 249 Bangladesh.

250

251 CONCLUSION

We report the circulation of Clade I *C. auris* in Bangladesh along with the emergence of the novel Clade VI detected patients in the ICU and NICU. Bangladesh remains the hub of this novel clade since a Clade VI isolate was also found in the blood of a Bangladeshi patient airlifted in Singapore in 2018. It is critical that we enforce nation-wide genomic surveillance to better understand the emergence and transmission of this novel clade in Bangladesh.

257

258 MATERIALS AND METHODS

259 Isolate Selection.

From August-September 2021, as part of ongoing hospital surveillance, we identified a total of 260 261 60 Candida auris isolates and archived these isolates at the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) Mycology Laboratory. Isolates were cultured from 262 263 skin swab samples from both axilla and groin for screening the patients admitted in the ICU 264 and NICU of two tertiary care hospitals (one public and one private). In addition to onadmission screening sample, subsequent follow up samples were collected- after 72 hours of 265 admission and before shifting from ICU- from patients to identify nosocomial colonization. 266 [32]. Isolates from ICU patients were termed as BD-ICU, and isolates from NICU patients 267 268 were termed BD- NICU throughout the manuscript.

269 DNA Extraction and Whole Genome Sequencing.

Ten *C. auris* isolates were randomly selected and retrieved from -80° C storage and grown on CHROMagarTM Candida Plus media for presumptive identification of *C. auris*. Pure *C. auris* colonies were transferred from CHROMagarTM plate to SDA plate and incubated at $37^{\circ}C$ for 72 hours. Genomic DNA of the *C. auris* isolates was extracted using the Qiagen DNAeasy Blood & Tissue Kit, and the Illumina DNA Prep kit (Illumina Inc., San Diego, California, USA)

was used for the construction of DNA libraries. Sequencing was performed on Illumina
NextSeq 550 platform with 2x150 bp cycles at icddr,b Genome Centre.

277 Variant Calling and Phylogenetic Analysis.

278 To investigate the origin and possible route of transmission of sequenced C. auris isolates from 279 Bangladesh, phylogenetic analysis was performed using the whole-genome sequences. A total of 25 isolates representative of C. auris clades I – V were also included in this analysis (File 280 281 S2). Quality control, single nucleotide polymorphism (SNP) calling, and phylogenetic analysis performed reference-based 282 were using the pipeline, MycoSNP, v1.4 283 (https://github.com/CDCgov/mycosnp-nf) with default parameters and using assembly B11205 (Accession no. GCA 016772135.1) generated from an isolate from India [33]. In brief, the 284 MycoSNP workflow masks repetitive regions and indexes the reference genome in preparation 285 286 for read alignment and snp calling. Paired-end reads were trimmed and filtered for low quality 287 data. Samples, with at least 20X coverage and a % GC content between 42-47.5%, were used 288 for alignment to the reference genome using the BWA [34] and pre-processed for downstream 289 single-nucleotide polymorphism (SNP) analysis using GATK[35]. GATK HaplotypeCaller 290 function is used for haplotype calling the processed BAM files from each isolate. The ploidy 291 parameter for C. auris is set to haploid. HaplotypeCaller uses the PairHMM (Pair Hidden Markov Models) algorithm and performs pairwise alignment. Then, the resulting individual 292 293 gVCF files are merged into a single multi-sample gVCF file by CombineGVCFs function. 294 Next, the *GenotypeGVCFs* function performs SNP calling from this single gVCF file which 295 results in a VCF file with all samples genotyped. GATK's VariantFiltration function was used 296 to filter SNP sites based on the QualityByDepth (QD), FisherStrand Score (FS) and 297 RMSMappingQuality (MQ) parameters using filtering expression: "QD $< 2.0 \parallel FS > 60.0 \parallel$ MQ < 40.0". Additional customized SNP filters were applied based on parameters such as 298 299 Genotype Quality (GQ), allele depth (AD), and depth (DP) using following criterion: : $GQ \ge$

50, AD \ge 80%, DP \ge 10. The MycoSNP workflow recovered all SNP alleles from the VCF files 300 using a Python script "vcfSnpsToFasta.py" (https://github.com/broadinstitute/broad-301 fungalgroup/tree/master/scripts/SNPs) to create an SNP alignment in multi-fasta format [33]. 302 303 To construct Maximum Likelihood (ML) phylogenetic trees from SNP alignment, RAxML v8.2.12 [36] was utilized with the Generalized Time-Reversible model and a Gamma 304 distribution (GTRGAMMA) to account for site-specific rate variation. Support for the ML 305 306 phylogenetic trees were evaluated through 1000 bootstrap replicates of the alignment. The resulting trees were visualized using iTol v5.5 [37]. 307

308 Mutational Characterization.

De novo assembly was performed using SPAdes v.3.15.5 to generate assemblies and assessed 309 with Quast v.5.5.0 [38, 39]. The assembly reports were summarized in File S5 in the 310 311 supplemental material. A custom python script was generated to map ERG11 (F126L, Y132F, K143R, and F444L), CDR1 (V704L), TAC1B (S611P) and MRR1A (N647T) for azole 312 313 resistance, FCY1 (S70R) and FUR1 (1 Δ 33, and F211I) for 5-flucytocine resistance and FKS1 (S639Y/P/F, and F635C) genes for echinocandin resistance. Since the molecular mechanism 314 315 of amphotericin B is not well established, we also investigated known mutations in ERG3 316 (S58T) and ERG6 (G403T, and R97fs) genes involved in ergosterol biosynthetic pathways 317 which are postulated to confer amphotericin B resistance [14, 40].

318 Antifungal Susceptibility Testing (AFST).

To assess the resistance of *C. auris* to antifungals, antifungal susceptibility testing (AFST) was 319 320 performed using Gradient Diffusion Strips method or E-test (OFD-500-P03: https://www.cdc.gov/fungal/lab-professionals/pdf/afst-yeasts-h.pdf) according to Clinical and 321 Laboratory Standards Institute (CLSI) guidelines [41]. The E-test gradient strips of 322 fluconazole, voriconazole, caspofungin, and amphotericin B was obtained from Biomerieux. 323 The reference number and lot number of corresponding anti-fungal strip are provided in File 324

325 S6. The fluconazole concentration gradient ranged from 256 to 0.016 μ g/ml while for other 326 antifungals, it ranged from 32 to 0.002 µg/ml. The antifungals used in this study for AFST are 327 representative of 3 major classes of antifungals (azoles, echinocandins and polyenes). The 328 culture media used were Sabouraud dextrose agar (SDA; Becton Dickinson) and Roswell Park 329 Memorial Institute medium 1640 (RPMI-1640; Sigma-Aldrich). Currently, there are no established minimum inhibition concentration (MIC) breakpoints for C. auris. CDC proposed 330 331 tentative breakpoints for fluconazole (\geq 32 mg/L), voriconazole (\geq 1mg/L), caspofungin (\geq 2 mg/L), anidulafungin (≥ 4 mg/L), micafungin (≥ 4 mg/L), amphotericin B (≥ 2 mg/L) and other 332 333 antifungals [7, 18, 42].

The *C. auris* isolates from this study were also tested for susceptibility to 5-flucytosine by disk 334 diffusion method outlined by CLSI-M60 guidelines [43]. The assays were performed using 335 336 fungal suspension adjusted to match the turbidity of a 0.5 McFarland standard. The antifungal disk for Flucytosine (AFY) 10 µg was purchased from Liofilchem[®], Italy). Mueller Hinton II 337 338 Agar (MHA; BD), Sabouraud Dextrose Agar (SDA; BD) and Roswell Park Memorial Institute 339 Medium 1640 (RPMI-1640; Sigma–Aldrich) was used for preparation of media of the *C. auris* isolates. The reference and lot number of corresponding agar and media are provided in File 340 341 S6. The disks were placed on to the inoculum media and the plates were incubated at $35^{\circ}C(\pm 2^{\circ}C)$ for 18-24 hours. After 24 hours, the plates were examined and the zones of 342 inhibition diameter (ZOD) around the discs were measured in millimeters (mm). The inhibition 343 344 zone diameters (mm) were interpreted as Susceptible (S), Intermediate (I) and Resistant (R) based on established clinical breakpoints provided by CLSI. Susceptibility to 5-flucytosine was 345 also tested via automated VITEK[®]2 system using an AST-YS09 card as per the manufacturer's 346 instructions. The time and temperature of incubation was similar to disk diffusion assay 347 $(18 - 24 hours at 35 \pm 2^{\circ}C)$ but the results were expressed as MICs. The MIC calling range 348 was 1 to 64 mg/L for 5-flucytosine. Since the VITEK[®]2 system lacks species-specific MICs 349

for *C. auris*, the species was modified to different *Candida* spp. to obtain MICs for *C. auris*isolates. Notably, the MIC values remained consistent irrespective of the species assigned when
retrieving MIC data for *C. auris* across all drugs. As *C. duobushaemulonii* closely related to *C. auris* and belongs to the *C. haemulonii* complex , analysis was based on MICs retrieved from
this species [44, 45].

356 Ethical approval.

The study was approved by icddr,b Research Review Committee and Ethical Review Committee. The approval protocol number was PR-20122. All patients participated in this study gave written informed consent for donating the samples.

360 Data availability.

361 The sequencing data sets generated during this study are available in the Sequence Read362 Archive repository under projects PRJNA981511.

363 ACKNOWLEDGMENTS

The study was funded by Centre for Disease Control and Prevention, Atlanta, USA, through cooperative agreement. We also gratefully acknowledge icddr,b core donors (Govt. of Bangladesh and Canada) for their unrestricted support and commitment to icddr,b's research efforts.

368

369 Conceptualization, T.K., N.I.F., M.J., F.C., and M.R.; data curation, T.K., N.I.F., M.M.H., S.M.,

370 A.H., and D.S.; formal analysis, T.K., N.I.F., M.M.H., A.H., S.B.M., D.S., and L.A.P.;

investigation, T.K., N.I.F., S.M., DA, M.J., N.A.C., F.C., and M.R.; methodology, T.K., N.I.F.,

372 M.M.H., A.H., S.B.M., DA, L.A.P., and M.J.; validation, T.K., N.I.F., A.H., S.B.M., D.S., DA,

373 L.A.P., M.J., F.C., and M.R.; supervision, F.C., and M.R.; visualization, T.K., M.M.H., L.A.P.,

374	and N.A.C.; writing - original draft, T.K., N.I.F., and M.R.; writing -review & editing, T.K.,						
375	N.I.F., M.M.H., S.M., A.H., S.B.M., D.S., DA, L.A.P., M.J., N.A.C., F.C., and M.R.						
376							
377	Disclaimer: The findings and conclusions of this report are those of the authors and do not						
378	necessarily represent the official position of the Centers for Disease Control (CDC). The						
379	Sample IDs and Sequencing IDs used in this manuscript were randomly assigned, did not						
380	correspond to any of the hospital generated original IDs and were not disclosed to anyone						
381	outside the research group, not even to hospital staff or patients themselves.						
382							
383	Supplemental Material						
384	Fig S1: Phenotypic differences observed between BD Clade I and Clade VI isolates of Candida						
385	auris at different timelines (A) 24 hours (B) 48 hours and (C) 72 hours.						
386	File S1: Patient metadata of BD Candida auris isolates.						
387	File S2: Candida auris isolates used in this representing known five clades.						
388	File S3: Quality metrices of BD Candida auris isolates generated by MycoSNP v1.4.						
389	File S4: SNP distances generated by MycoSNP v1.4 for all <i>Candida auris</i> isolates in this study.						
390	File S5: Assembly metrices of BD Candida auris isolates.						
391	File S6: Anti-fungal strips, agar, and media used in this study with reference number and lot						
392	number.						
393							
394	REFERENCES						
395 396 207	1. Muñoz, J.F., et al., <i>Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species.</i> Nature communications, 2018. 9 (1): p. 5246						
398 399 400	 Satoh, K., et al., Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiology and immunology 2009 52(1): p. 41-44 						
401 402	 Spruijtenburg, B., et al., Confirmation of fifth Candida auris clade by whole genome sequencing. Emerging Microbes & Infections, 2022. 11(1): p. 2405-2411. 						

403 4. Chowdhary, A., et al., *Multidrug-resistant Candida auris infections in critically ill*404 *coronavirus disease patients, India, April–July 2020.* Emerging infectious diseases,
405 2020. 26(11): p. 2694.

- 406 5. Osei Sekyere, J., Candida auris: A systematic review and meta-analysis of current
 407 updates on an emerging multidrug-resistant pathogen. Microbiologyopen, 2018. 7(4):
 408 p. e00578.
- 409 6. Lockhart, S.R., M.M. Lyman, and D.J. Sexton, *Tools for detecting a "superbug": updates*410 *on Candida auris testing.* Journal of Clinical Microbiology, 2022. **60**(5): p. e00808-21.
- 411 7. Lockhart, S.R., et al., *Simultaneous emergence of multidrug-resistant Candida auris on*412 *3 continents confirmed by whole-genome sequencing and epidemiological analyses.*413 Clinical Infectious Diseases, 2017. 64(2): p. 134-140.
- 414 8. Chow, N.A., et al., *Tracing the evolutionary history and global expansion of Candida*415 *auris using population genomic analyses.* MBio, 2020. **11**(2): p. 10.1128/mbio. 03364416 19.
- 417 9. Forsberg, K., et al., *Candida auris: The recent emergence of a multidrug-resistant*418 *fungal pathogen.* Medical mycology, 2019. 57(1): p. 1-12.
- Sharma, C., et al., Whole genome sequencing of emerging multidrug resistant Candida *auris isolates in India demonstrates low genetic variation.* New microbes and new
 infections, 2016. 13: p. 77-82.
- 422 11. Rhodes, J., et al., *Genomic epidemiology of the UK outbreak of the emerging human*423 *fungal pathogen Candida auris.* Emerging microbes & infections, 2018. 7(1): p. 1-12.
- Chow, N.A., et al., *Multiple introductions and subsequent transmission of multidrug- resistant Candida auris in the USA: a molecular epidemiological survey.* The Lancet
 Infectious Diseases, 2018. 18(12): p. 1377-1384.
- 427 13. Lockhart, S.R., A. Chowdhary, and J.A. Gold, *The rapid emergence of antifungal-*428 *resistant human-pathogenic fungi.* Nature Reviews Microbiology, 2023: p. 1-15.
- 429 14. Maphanga, T.G., et al., *In vitro antifungal resistance of Candida auris isolates from*430 *bloodstream infections, South Africa.* Antimicrobial agents and chemotherapy, 2021.
 431 65(9): p. 10.1128/aac. 00517-21.
- 432 15. Armaki, M.T., et al., *First fluconazole-resistant Candida auris isolated from fungal otitis*433 *in Iran.* Current medical mycology, 2021. **7**(1): p. 51.
- 434 16. Safari, F., et al., A chronic autochthonous fifth clade case of Candida auris otomycosis
 435 in Iran. Mycopathologia, 2022. 187(1): p. 121-127.
- 436 17. Mhlanga, M., et al., *Multilocus sequence typing of azole-resistant Candida auris strains,*437 South Africa. Southern African Journal of Infectious Diseases, 2020. **35**(1): p. 1-7.
- 438 18. Chowdhary, A., et al., A multicentre study of antifungal susceptibility patterns among
 439 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in
 440 azole and echinocandin resistance. Journal of Antimicrobial Chemotherapy, 2018.
 441 73(4): p. 891-899.
- 442 19. Berkow, E.L., D. Angulo, and S.R. Lockhart, *In vitro activity of a novel glucan synthase*443 *inhibitor, SCY-078, against clinical isolates of Candida auris.* Antimicrobial agents and
 444 chemotherapy, 2017. 61(7).
- 44520.Jacobs, S.E., et al., Candida auris pan-drug-resistant to four classes of antifungal446agents. Antimicrobial Agents and Chemotherapy, 2022. 66(7): p. e00053-22.
- 447 21. Kordalewska, M., et al., Understanding echinocandin resistance in the emerging
 448 pathogen Candida auris. Antimicrobial agents and chemotherapy, 2018. 62(6): p.
 449 10.1128/aac. 00238-18.

- 450 22. Escandón, P., et al., *Molecular epidemiology of Candida auris in Colombia reveals a*451 *highly related, countrywide colonization with regional patterns in amphotericin B*452 *resistance.* Clinical Infectious Diseases, 2019. 68(1): p. 15-21.
- 453 23. Gugnani, H.C., et al., Burden of serious fungal infections in Bangladesh. European
 454 Journal of Clinical Microbiology & Infectious Diseases, 2017. 36: p. 993-997.
- 455 24. Islam, M.T., et al., *Emergence of wheat blast in Bangladesh was caused by a South* 456 *American lineage of Magnaporthe oryzae.* BMC biology, 2016. **14**(1): p. 1-11.
- 457 25. Fisher, M.C., et al., *Threats posed by the fungal kingdom to humans, wildlife, and* 458 *agriculture.* MBio, 2020. **11**(3): p. 10.1128/mbio. 00449-20.
- Chowdhary, A., et al., *Multidrug-resistant endemic clonal strain of Candida auris in India*. European journal of clinical microbiology & infectious diseases, 2014. 33: p. 919926.
- 462 27. Clancy, C.J. and M.H. Nguyen, *Emergence of Candida auris: an international call to*463 *arms*. 2017, Oxford University Press US. p. 141-143.
- 464 28. Dutta, S., et al., *Detection of Candida auris and its antifungal susceptibility: first report*465 *from Bangladesh.* IMC Journal of Medical Science, 2019. **13**(2): p. 18-22.
- Sathi, F.A., et al., *Prevalence and antifungal susceptibility of clinically relevant candida species, identification of candida auris and kodamaea ohmeri in Bangladesh.* Tropical
 Medicine and Infectious Disease, 2022. **7**(9): p. 211.
- Tan, Y.E., et al., *Candida auris in Singapore: Genomic epidemiology, antifungal drug resistance, and identification using the updated 8.01 VITEK® 2 system.* International
 journal of antimicrobial agents, 2019. 54(6): p. 709-715.
- 472 31. Suphavilai, C., et al., *Discovery of the sixth Candida auris clade in Singapore*. medRxiv,
 473 2023: p. 2023.08. 01.23293435.
- 474 32. Roberts, S.C., et al., *Genetic evaluation of nosocomial Candida auris transmission*.
 475 Journal of clinical microbiology, 2021. 59(4): p. 10.1128/jcm. 02252-20.
- 476 33. Bagal, U.R., et al., *MycoSNP: a portable workflow for performing whole-genome*477 *sequencing analysis of Candida auris,* in *Candida auris: Methods and Protocols.* 2022,
 478 Springer. p. 215-228.
- 479 34. Li, H., Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.
 480 arXiv preprint arXiv:1303.3997, 2013.
- 481 35. McKenna, A., et al., *The Genome Analysis Toolkit: a MapReduce framework for*482 *analyzing next-generation DNA sequencing data.* Genome research, 2010. 20(9): p.
 483 1297-1303.
- 484 36. Stamatakis, A., *RAxML version 8: a tool for phylogenetic analysis and post-analysis of*485 *large phylogenies.* Bioinformatics, 2014. **30**(9): p. 1312-1313.
- 486 37. Letunic, I. and P. Bork, *Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation*. Nucleic acids research, 2021. **49**(W1): p. W293-W296.
- 488 38. Bankevich, A., et al., SPAdes: a new genome assembly algorithm and its applications
 489 to single-cell sequencing. Journal of computational biology, 2012. 19(5): p. 455-477.
- 490 39. Gurevich, A., et al., *QUAST: quality assessment tool for genome assemblies.*491 Bioinformatics, 2013. **29**(8): p. 1072-1075.
- 492 40. Rybak, J.M., et al., *In vivo emergence of high-level resistance during treatment reveals*493 *the first identified mechanism of amphotericin B resistance in Candida auris.* Clinical
 494 Microbiology and Infection, 2022. 28(6): p. 838-843.
- 495 41. Clinical and Laboratory Standards Institute (2008) Reference method for broth dilution
 496 antifungal susceptibility testing of yeasts, 3rd ed. Approved standard. CLSI document

- 497 *M27-A3. Clinical and Laboratory Standards Institute, Wayne*. 2008; 3rd:[Available 498 from: <u>https://clsi.org/media/1461/m27a3_sample.pdf</u>.
- 499 42. CDC. Candida auris Antifungal Susceptibility Testing. 2020; Available from:
 500 <u>https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html</u>
- 50143.CLSI, Performance standards for antifungal susceptibility testing of yeasts.2017,502Clinical and Laboratory Standards Wayne, PA.
- 50344.Xie, O., et al., Candida duobushaemulonii sepsis and Candida auris co-isolation504following hospitalisation in Vietnam. Pathology, 2020. 52(5): p. 590-591.
- 505 45. Siopi, M., et al., Evaluation of the Vitek 2 system for antifungal susceptibility testing of
 506 Candida auris using a representative international panel of clinical isolates:
 507 overestimation of amphotericin B resistance and underestimation of fluconazole
 508 resistance. Journal of Clinical Microbiology, 2024: p. e01528-23.
- 509

Sample ID	Clade	Patient Age Range (Years)	Collection Source	Collection Date (Year)	Travel History	Colonization Type
101019	Clade I	56-60	ICU	2021	No	HAI
101008	Clade I	41-45	ICU	2021	No	HAI
101009	Clade I	31-35	ICU	2021	No	HAI
101022	Clade I	31-35	ICU	2021	UAE	HAI
101077	Clade I	11-15	ICU	2021	No	On admission
101082	Clade I	21-25	ICU	2021	No	On admission
101101	Clade I	51-55	ICU	2021	No	On admission
101087	Clade I	16-20	ICU	2021	No	On admission
102096	Clade VI	0-5	NICU	2021	No	On admission
102170	Clade VI	0-5	NICU	2021	No	On admission

TABLE 1: Patient metadata of sequenced *Candida auris* isolates.

*HAI = Hospital acquired infection.

Hour	Colony Characteristics	Clade I	Clade VI	Comments
	Size	Tiny	Large	
24	Morphology	Mated	Isolated	Difference in colony morphology
	Color	Whitish	Whitish Blue	
	Size	Medium Mucoid	Large Mucoid	
48	Morphology	Isolated	Single Isolated	Difference in colony size and color
	Color	Whitish	Whitish Blue	
	Size	Large Mucoid	Large Mucoid	
72	Morphology	Single Isolated	Single Isolated	Both Clades show similar characteristics
	Color	Whitish Blue	Whitish Blue	

TABLE 2: Phenotypic differences observed between BD Clade I and Clade VI isolates of Candida auris at different timelines (A) 24 hours (B) 48 hours and (C) 72 hours.

Sample ID	Clade	Azole		Echinocandin	Polyene	Polyene Gene Mutations	
Sample ID	Claut	Fluconazole	Voriconazole	Caspofungin	Amphotericin B	ERG11	FCY1
101019	Clade I	256	32	0.19	1	Y132F	S70R
101008	Clade I	256	32	0.25	1	Y132F	S70R
101009	Clade I	256	32	0.38	1	Y132F	S70R
101022	Clade I	256	32	0.125	2	Y132F	S70R
101077	Clade I	256	32	0.25	0.5	Y132F	S70R
101082	Clade I	256	32	0.19	0.75	Y132F	S70R
101101	Clade I	256	32	0.25	0.5	Y132F	S70R
101087	Clade I	256	32	0.25	1	Y132F	S70R
102096	Clade VI	6	0.19	0.125	0.75	-	-
102170	Clade VI	8	0.19	0.125	2	-	-

TABLE 3: Results of known mutation	ation analysis and	antifungal su	usceptibility test f	for azoles, polyenes, a	nd echinocandins.
	-	U	1 2		

Sampla ID	Clada	Disk Diffusion		VIT	Gene Mutation	
Sample ID	Claue	ZOD (mm)	Resistance Profile	MIC (mg/L)	Resistance Profile	FCY1
101019	Clade I	6	R	≥ 64	R	S70R
101008	Clade I	36	S	≤ 1	S	S70R
101009	Clade I	30	S	≤ 1	S	S70R
101022	Clade I	35	S	≤ 1	S	S70R
101077	Clade I	34	S	≤ 1	S	S70R
101082	Clade I	34	S	≤ 1	S	S70R
101101	Clade I	30	S	≤ 1	S	S70R
101087	Clade I	33	S	≤ 1	S	S70R
102096	Clade VI	32	S	≤ 1	S	-
102170	Clade VI	31	S	≤ 1	S	-

TABLE 4: Results of 5-flucytosine antifungal susceptibility test by disk diffusion and VITEK[®]2 method.

*S = Susceptible, I = Intermediate, R = Resistant. The categorization of resistance was based on established clinical breakpoints provided by CLSI.

Α.

Country

-

	Bangladesh		B11205
m	edRxiv preprint doi: https://doi.org/10.110	1/2024.04.12.24305665; this version posted April 17, 2024. The copyright holder for this preprint	- India B11207
	(which was not certified by peer review Canada It is m	v) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ade available under a CC-BY-NC 4.0 International license.	- Pakistan B11116
			- USA NJ B11858
	Colombia		- UK 15B5
			- 101019
	India		- UAE B14000
	C. Laws		- 101022
	Iran		- 101087
	Ieraol		101077
-	131201		101009
	Japan		- 101008
			101101
	Kenya		- 101082
			USA IN B12631
	Pakistan		Spain AA-200
	Deserve		South Africa B1122
_	Panama		
	South Africa	1	Canada D42402
	South Anica		Canada B13463
	South Korea		USA EL B1/308
			- Japan B11220
	Spain		South Korea B1180
	10002		Iran IRFC 4050
	UAE		Iran TMML616
	LIK .		Iran TMML617
	UK		Iran MRL40
	USA		Iran IFRC2087
	1.5.5.500		102096
	Venezuela		- 102170
			Venezuela B11243
Clad	es		- Israel B11896
Jiuu			- Panama B12107
(Clade I (South Asian)		LISA IL D11942
			00A IL B 11042
(Clade II (East Asian)	Tree Scale. 0.1	
	Clade III (African)		
	Clade IV (South American)		
	lade V (Iranian)	B.	
		19533	02096
(Clade VI	1	02170
2			enezuela B11243
		21038	araal D11000
			310ELD 1 1090
		F	'anama B12107
		C	olombia B12279



USA ILB11842

500



Clades o

5

C.



